Prenuvo Expands Health Services with New Offerings and $120M Funding

Innovative preventative health company Prenuvo has announced the addition of three new health assessments to its suite of diagnostic services. These include a blood test, a neurological scan, and a body composition analysis, all recently approved by the U.S. Food and Drug Administration. In alignment with its mission to provide comprehensive health diagnostics, Prenuvo's offerings seek to offer patients a more complete understanding of their health status. Alongside the new services, Prenuvo has successfully closed a $120 million investment round, co-led by prominent firms Left Lane Capital, Forerunner Ventures, and Felicis, an existing investor in the company. This funding is poised to bolster the company's expansion and innovation initiatives. Prenuvo, which is recognized for its full-body MRI scan, priced at $2,500, will now offer a combined package of the scan and the new assessments for a fee of $3,999. Notably, Prenuvo has demonstrated financial robustness, having generated $100 million in revenue last year, and has achieved profitability.